Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 18, 2025, titled "Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".